ITCI News and Press, Intra-Cellular Therapies Inc. From 08/02/23

2023-08-02 14:28:44 ET Intra-Cellular Therapies ( NASDAQ: ITCI ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$0.59 and the consensus Revenue Estimate is $106.81M (+92.1% Y/Y). Over the last 1 ...

NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced it will host a conference call and live webcast ...

NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will present at the Goldman Sachs 44th Annual...

NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced several CAPLYTA data presentations at the America...

2023-05-25 19:51:46 ET Summary Intra-Cellular's drug Caplyta (lumateperone) is advancing through trials for major depressive disorder (MDD), expanding its approved uses beyond schizophrenia and bipolar depression. Caplyta faces exclusivity expiration in December 2024, compelling I...

2023-05-04 13:53:06 ET Intra-Cellular Therapies, Inc. (ITCI) Q1 2023 Earnings Conference Call May 4, 2023 8:30 AM ET Company Participants Juan Sanchez – Vice President-Corporate Communications and Investor Relations Sharon Mates – Chairman and Chief Exe...

2023-05-04 07:37:59 ET Intra-Cellular Therapies press release ( NASDAQ: ITCI ): Q1 GAAP EPS of -$0.46 beats by $0.16 . Revenue of $95.31M (+172.3% Y/Y) beats by $2.9M . CAPLYTA Q1 2023 net product sales were $94.7 million, compared to $34.8 million for t...

Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023 net product sales were $94.7 million, compared to $34.8 million for the same period in 2022, representing a 173% increase Q1 2023 CAPLYTA total prescriptions increa...

2023-05-03 13:39:31 ET Intra-Cellular Therapies ( NASDAQ: ITCI ) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open. The consensus EPS Estimate is -$0.62 (+20.5% Y/Y) and the consensus Revenue Estimate is $92.41M (+164.0% Y/Y). Over t...

2023-05-01 08:33:59 ET A stronger-than expected earnings season is bolstering belief that an EPS recovery can arrive in the second half of the year, but at the same time leading macro data have slowed, according to Morgan Stanley strategist Mike Wilson. Late last week, concerns about ...